GWAS

Rgenta Therapeutics to Present at the 19th Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
Wednesday, February 21, 2024
Traffic barrier, MLH1, PMS2, Huntington's disease, GWAS, FXS, Conference, DM1, MSH3, PMS1, RNA, Therapy, FAN1, Gene, FRDA, CSO, Fragile X syndrome, Friedreich's ataxia, DNA, Vaccine

CAMBRIDGE, Mass., Feb. 21, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced it will participate at the 19th Annual Huntington's Disease Therapeutics Conference being held February 26-29, 2024, in Palm Springs, California.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 21, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced it will participate at the 19th Annual Huntington's Disease Therapeutics Conference being held February 26-29, 2024, in Palm Springs, California.
  • As part of the annual conference, Travis Wager, Ph.D., President & CSO of Rgenta will participate in the Targeting the DNA repair machinery to modulate somatic instability session on Tuesday, February 27, 2024 at 2:00 PM PT.
  • To date, there has been a lack of successful strategies for directly targeting the PMS1 protein with small molecule inhibitors.
  • For more information about the event, please visit the conference website .

OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASH

Retrieved on: 
Tuesday, February 13, 2024
Health, Genetics, Fitness & Nutrition, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, KOSDAQ, Genome-wide association study, Inflammation, Obesity, Hope, GWAS, Safety, MASH, Patient, Gene, Clinical trial, Cirrhosis, NASH, RNA interference, Non-alcoholic fatty liver disease

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the first participant was dosed today with OLX75016.

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the first participant was dosed today with OLX75016.
  • OLX75016 is being developed to provide a novel treatment approach for metabolic dysfunctions associated with non-alcoholic fatty liver disease linked to obesity.
  • The phase 1 trial is ongoing in Brisbane, Australia.
  • This is how we believe OLX75016 is set apart, and we anticipate this novel therapeutic to bring hope to patients with multiple metabolic diseases, starting in phase 1 clinical trial."

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Retrieved on: 
Wednesday, January 31, 2024
Health, Genetics, Health Technology, Research, Science, Biotechnology, Genomics, Oxford Nanopore Technologies, Growth, DNA, Gene, 3D, University, Database, Weill Cornell Medicine, CSO, Genome-wide association study, Master of Science, Wellcome Sanger Institute, GWAS, Algorithm, Molecular biology, Doctor of Philosophy, Antibiotics

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).
  • Dan’s deep expertise in genomics technology development and commercialisation will be key to achieving the next phase of Enhanc3D Genomics’ growth.
  • Dr Hazel Jones, Chief Operating Officer and interim Chief Executive Officer, Enhanc3D Genomics, said: “Dan joins us at an exciting stage in the Company’s development as we begin to steer towards commercialisation.
  • I look forward to working alongside Dan as he joins the team.”
    Dr Dan Turner, Chief Scientific Officer, Enhanc3D Genomics, commented: “Enhanc3D Genomics has an exceptional reputation in the field of 3D genomics, and I’m delighted to take this opportunity to help drive the development of its technology further.

Pairwise Earns USDA Exemption Confirmations for Genomic Edits in Berries

Retrieved on: 
Friday, January 26, 2024
Regulation, Pairwise, Botany, Rubus, Research, North Carolina State University, Government, Biodiversity, Food, Breeding, University, CRISPR, Science, GWAS, USDA, Climate change, Cornell University, Fulcrum, BlackBerry, Genome, Plant, Gene editing, Agriculture

Per the USDA, plants with edits that meet the requirements for these exemptions are “achievable by conventional breeding.” These new exemptions represent an array of traits that are important to both consumers and growers.

Key Points: 
  • Per the USDA, plants with edits that meet the requirements for these exemptions are “achievable by conventional breeding.” These new exemptions represent an array of traits that are important to both consumers and growers.
  • These new nine bring the total number of Pairwise’s confirmed trait exemptions for berries to 19, which include seedless, thornless and higher-yielding traits in blackberry and black raspberry.
  • The company’s total number of confirmed exemptions is now 21, which it achieved in 15 months.
  • “Successfully securing these exemptions speaks to the power of the Pairwise Fulcrum platform and our ability to deliver differentiated products,” Dan Jenkins, Pairwise Vice President of Regulatory and Government Affairs.

Complete Genomics and Gencove Announce agreement at Plant and Animal Genome Conference (PAG 31) to offer a bundled solution for low-pass whole genome sequencing

Retrieved on: 
Tuesday, January 16, 2024
Entrepreneurship, Research, SAN, DNA, Partnership, Whole genome sequencing, GWAS, Complete Genomics, Genomics, Genome, Antibiotics

The partnership will combine Gencove's platform for data analytics and management with Complete Genomics' sequencing products and automation capabilities via high-throughput nucleic acid extraction, automated library preparation on its DNBSEQ-T7RS* and DNBSEQ-T20X2RS* sequencers.

Key Points: 
  • The partnership will combine Gencove's platform for data analytics and management with Complete Genomics' sequencing products and automation capabilities via high-throughput nucleic acid extraction, automated library preparation on its DNBSEQ-T7RS* and DNBSEQ-T20X2RS* sequencers.
  • "While low-pass whole genome sequencing has long been touted as an advanced method for everything from GWAS analysis to genotyping for molecular breeding, its potential hasn't been fully realized.
  • "Through this partnership with Complete Genomics, we're enabling higher throughput results at a lower cost per sample, making more affordable sequencing accessible to more researchers," said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove.
  • "It will provide the kind of comprehensive genome coverage that leads to the discovery of novel variants."

Genetic Testing's Role in Personalized Medicine and Targeted Therapies for Respiratory Conditions - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Health, Genetics, Personalized medicine, COPD, Genome-wide association study, Disorder, Prevalence, Granulomatous–lymphocytic interstitial lung disease, Privacy, Risk, Diagnosis, GWAS, Respiratory disease, Marker beacon, Region, Genetic testing, Health information management, Growth, Chronic obstructive pulmonary disease, Asthma, Cystic fibrosis, Agriculture, Pharmaceutical industry, Vaccine, Medical device

Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.

Key Points: 
  • Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.
  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.
  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.

Enhanc3D Genomics Expands Leadership Team With the Appointment of Hazel Jones as Chief Operating Officer

Retrieved on: 
Monday, November 6, 2023
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, 3D, Combination, Genomics, AstraZeneca, Integrated business planning, Bachelor of Science, Doctor of Philosophy, Database, GWAS, University, Cancer research, Gene, Genome-wide association study, Algorithm, Clinical data management, Patient, Diagnosis, DNA, Nursing, Antibiotics, Biochemistry, Pharmacology

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.
  • Hazel has over 10 years of senior leadership experience in oncology research.
  • Prior to joining Enhanc3D Genomics, Hazel held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D.
  • I am delighted to welcome Hazel to the team.”
    Dr Hazel Jones, Chief Operating Officer, Enhanc3D Genomics, added: “I’m delighted to join the team at such an exciting stage of the Company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”
    For more information about Enhanc3D Genomics, please visit: www.enhanc3dgenomics.com

Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics

Retrieved on: 
Thursday, October 5, 2023
Drug repositioning, Health, UK Biobank, Biomarker, Drug development, Proteogenomics, Data, Proteomics, Safety, UKB, Kingdom of Poland, CV, AstraZeneca, GWAS, Gene, Protein, Publication, Drug discovery, Biobank, Volunteering, Genomics, Research, Sun, Vaccine, Pharmaceutical industry, Nature

The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.

Key Points: 
  • The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 biopharmaceutical companies generated new proteomic data from accessing the UK Biobank.
  • Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples.
  • The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts.
  • “These landmark publications are a powerful demonstration of how next-gen proteomics can reveal crucial biological insights not seen with traditional genomics alone.

BioBam Launches OmicsBox 3.1: Revolutionizing Omics Data Analysis

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Professional Services, Software, Biotechnology, Data Analytics, Health, Science, Other Science, Abraxis BioScience, Single-cell analysis, B cell, Multimedia, GWAS, Genomics, RNA-Seq, UMI, Genetic variation, ONT, Mobile phone, BioBam Bioinformatics

BioBam, the leading bioinformatics software company, is pleased to announce OmicsBox 3.1, its latest version packed with innovative features designed to empower researchers, scientists, and bioinformaticians in their pursuit of advanced omics data analysis and interpretation.

Key Points: 
  • BioBam, the leading bioinformatics software company, is pleased to announce OmicsBox 3.1, its latest version packed with innovative features designed to empower researchers, scientists, and bioinformaticians in their pursuit of advanced omics data analysis and interpretation.
  • View the full release here: https://www.businesswire.com/news/home/20231003214238/en/
    OmicsBox has consistently led the way by providing comprehensive genomics, transcriptomics, and metagenomics data analysis tools.
  • This release represents a significant step forward, introducing new Single-Cell analysis capabilities, strengthening Long-Read transcriptome analysis, and enhancing Genetic Variation analysis.
  • In the Long-Read Transcriptome data analysis, OmicsBox 3.1 introduces a new read aligner, complementing well-established tools like Flair, IsoSeq, and Sqanti.

Directing our Attention: Bridging the Gap in Human Genomics

Retrieved on: 
Friday, September 22, 2023
Therapy, Clinical trial, Genetics, Research, GWAS, Genomics, Immunotherapy, Patient, EHR, Medicine, Drug discovery, Health, LATAM, Vaccine, Pharmaceutical industry

While Genomics Association Studies (GWAS) has long been a cornerstone of genetic research, data has traditionally skewed towards European populations.

Key Points: 
  • While Genomics Association Studies (GWAS) has long been a cornerstone of genetic research, data has traditionally skewed towards European populations.
  • PreCheck Health, is embarking on a groundbreaking mission to reshape the landscape of diversity in genomics research.
  • In the realm of human genomics, common genetic variants, which occur in over 5% of the population, have received substantial attention.
  • By bridging the gap in human genomics research, PreCheck Health Services is opening doors to a more comprehensive understanding of genetic variance and its implications for drug discovery and patient care.